ASHISH C BHATIA
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology
- Where
- ITASCA, IL
- NPI
- 1073595690
- Received
- $550,400 in 759 records, 2019 to 2025 ($434,330 general, $116,070 research)
- As principal investigator
- $205,875 of research payments to others in 24 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 196 | $136,598 |
| 2025 | Research payment | 12 | $2,917 |
| 2024 | General payment | 137 | $105,361 |
| 2024 | Research payment | 1 | $2,386 |
| 2023 | General payment | 80 | $80,524 |
| 2022 | General payment | 43 | $4,980 |
| 2022 | Research payment | 3 | $70,985 |
| 2021 | General payment | 79 | $26,015 |
| 2020 | General payment | 56 | $32,847 |
| 2020 | Research payment | 1 | $18,800 |
| 2019 | General payment | 141 | $48,002 |
| 2019 | Research payment | 10 | $20,980 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 67 | $238,571 |
| Research payment | 27 | $116,070 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 15 | $73,345 |
| Honoraria | 16 | $43,150 |
| Travel and Lodging | 94 | $27,005 |
| Food and Beverage | 534 | $22,540 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 3 | $15,100 |
| Grant | 2 | $14,517 |
| Education | 1 | $99 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-21 | Solta Medical, a division of Bausch Health US, LLC | $32 | Food and Beverage | In-kind items and services | CLEAR+BRILLIANT | 2025 | |
| 2025-12-19 | Biofrontera Inc. | $750 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | Kowa Pharmaceuticals America, Inc. | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-12-01 | Incyte Corporation | $16 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-19 | Galderma Laboratories, L.P. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Kowa Pharmaceuticals America, Inc. | $91 | Food and Beverage | In-kind items and services | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-11-17 | Arcutis Biotherapeutics, Inc. | $3,375 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-17 | Arcutis Biotherapeutics, Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-13 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-13 | Galderma Laboratories, L.P. | $123 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-11 | Regeneron Healthcare Solutions, Inc. | $36 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-11-10 | REVANCE THERAPEUTICS, INC. | $91 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-11-03 | MIMEDX Group, Inc. | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-31 | Arcutis Biotherapeutics, Inc. | $95 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-22 | Arcutis Biotherapeutics, Inc. | $305 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-22 | Arcutis Biotherapeutics, Inc. | $305 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-22 | Arcutis Biotherapeutics, Inc. | $305 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-16 | Kowa Pharmaceuticals America, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-10-14 | Arcutis Biotherapeutics, Inc. | $4 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,400 | Consulting Fee | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-29 | Biofrontera Inc. | $818 | Grant | In-kind items and services | AMELUZ Drug, DERMATOLOGY | 2025 | |
| 2025-09-25 | Biofrontera Inc. | $13,699 | Grant | In-kind items and services | RHODOLED XL Device, DERMATOLOGY | 2025 | |
| 2025-09-25 | MIMEDX Group, Inc. | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-24 | UCB, Inc. | $36 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-22 | PFIZER INC. | $5,350 | Consulting Fee | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-22 | Solta Medical, a division of Bausch Health US, LLC | $62 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-20 | Galderma Laboratories, L.P. | $65 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-20 | Galderma Laboratories, L.P. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-18 | MERZ NORTH AMERICA, INC. | $75 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $5,250 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $3,000 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Arcutis Biotherapeutics, Inc. | $3,000 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-17 | Incyte Corporation | $94 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-17 | REVANCE THERAPEUTICS, INC. | $91 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-09-17 | GENZYME CORPORATION | $51 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-17 | Incyte Corporation | $10 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $90 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-09-16 | PFIZER INC. | $79 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-11 | MAYNE PHARMA COMMERCIAL LLC | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-08 | PFIZER INC. | $4,385 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-06 | Galderma Laboratories, L.P. | $63 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-04 | Incyte Corporation | $23 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-03 | MIMEDX Group, Inc. | $9,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-03 | MIMEDX Group, Inc. | $103 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-09-03 | PFIZER INC. | $84 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,400 | Consulting Fee | Cash or cash equivalent | ILUMYA Biological, Dermatology | 2025 | |
| 2025-08-28 | REVANCE THERAPEUTICS, INC. | $5,000 | Consulting Fee | Cash or cash equivalent | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-08-26 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-08-25 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-21 | UCB, Inc. | $9,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $479 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $86 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $59 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $22 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $21 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $1 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | UCB, Inc. | $1 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-08-20 | Solta Medical, a division of Bausch Health US, LLC | $435 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $80 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-20 | Lilly USA, LLC | $30 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-08-19 | REVANCE THERAPEUTICS, INC. | $42 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-08-19 | REVANCE THERAPEUTICS, INC. | $33 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-08-19 | Arcutis Biotherapeutics, Inc. | $1 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-15 | Galderma Laboratories, L.P. | $182 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-15 | REVANCE THERAPEUTICS, INC. | $82 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-08-15 | REVANCE THERAPEUTICS, INC. | $27 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-08-08 | PFIZER INC. | $156 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-07 | PFIZER INC. | $631 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-07 | PFIZER INC. | $163 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-07 | PFIZER INC. | $133 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $156 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $66 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $33 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $30 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $1 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-04 | MIMEDX Group, Inc. | $1,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-02 | UCB, Inc. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $257 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $211 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $125 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $106 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $45 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $38 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-30 | Janssen Biotech, Inc. | $37 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-29 | PFIZER INC. | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-23 | PFIZER INC. | $119 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-22 | PFIZER INC. | $710 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-22 | PFIZER INC. | $278 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-21 | Ortho Dermatologics, a division of Bausch Health US, LLC | $84 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-07-14 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-12 | Verrica Pharmaceuticals Inc. | $50 | Food and Beverage | In-kind items and services | YCANTH Drug, DERMATOLOGY | 2025 | |
| 2025-07-12 | Incyte Corporation | $44 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-07-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $31 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-10 | UCB, Inc. | $108 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-10 | Biofrontera Inc. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-09 | Arcutis Biotherapeutics, Inc. | $6,187 | Consulting Fee | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-09 | Arcutis Biotherapeutics, Inc. | $3,750 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-09 | MIMEDX Group, Inc. | $200 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-09 | Arcutis Biotherapeutics, Inc. | $192 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-09 | Arcutis Biotherapeutics, Inc. | $64 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-07 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-06-28 | Galderma Laboratories, L.P. | $85 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-24 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-06-24 | Arcutis Biotherapeutics, Inc. | $4 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-23 | REVANCE THERAPEUTICS, INC. | $80 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-06-21 | Arcutis Biotherapeutics, Inc. | $271 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-21 | Arcutis Biotherapeutics, Inc. | $138 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-21 | Arcutis Biotherapeutics, Inc. | $103 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-21 | Arcutis Biotherapeutics, Inc. | $92 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-20 | Arcutis Biotherapeutics, Inc. | $418 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-20 | Arcutis Biotherapeutics, Inc. | $303 | Travel and Lodging | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-06-20 | REVANCE THERAPEUTICS, INC. | $86 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-06-15 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-06-12 | Surgenex LLC | $27 | Food and Beverage | Cash or cash equivalent | SurGraft Biological, Wound Care | 2025 | |
| 2025-06-10 | MIMEDX Group, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-08 | Galderma Laboratories, L.P. | $53 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-05 | REVANCE THERAPEUTICS, INC. | $40 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-05-30 | MIMEDX Group, Inc. | $273 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-29 | MIMEDX Group, Inc. | $506 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-29 | MIMEDX Group, Inc. | $142 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-29 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-28 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-05-27 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-05-22 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-05-20 | Janssen Biotech, Inc. | $27 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-20 | Verrica Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | YCANTH Drug, DERMATOLOGY | 2025 | |
| 2025-05-17 | REVANCE THERAPEUTICS, INC. | $4 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-05-16 | Galderma Laboratories, L.P. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | $28 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-05-15 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-05-15 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-05-14 | SUN PHARMACEUTICAL INDUSTRIES INC. | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-12 | MIMEDX Group, Inc. | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-11 | UCB, Inc. | $34 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-10 | Blueprint Medicines Corporation | $59 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-05-10 | UCB, Inc. | $27 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-10 | LEO Pharma Inc. | $19 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-05-09 | LEO Pharma Inc. | $113 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-05-09 | Galderma Laboratories, L.P. | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-09 | UCB, Inc. | $12 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-05 | Incyte Corporation | $21 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-04-30 | Organogenesis Inc. | $25 | Food and Beverage | In-kind items and services | VIA MATRIX Medical Supply, WOUND CARE | 2025 | |
| 2025-04-30 | MIMEDX Group, Inc. | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-30 | MIMEDX Group, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-07 | Lilly USA, LLC | $31 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-04-02 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-03-26 | Lilly USA, LLC | $25 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-03-25 | Eli Lilly and Company | $1,084 | Research payment | In-kind items and services | TALTZ Drug, Immunology | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2025 |
| 2025-03-20 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-03-18 | MIMEDX Group, Inc. | $375 | Consulting Fee | Cash or cash equivalent | BOVINE COLLAGEN Device, WOUND CARE | 2025 | |
| 2025-03-13 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-03-10 | Regeneron Pharmaceuticals, Inc. | $268 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-03-09 | E.R. Squibb & Sons, L.L.C. | $105 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-03-07 | Incyte Corporation | $56 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-03-07 | UCB, Inc. | $9 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-03-03 | MIMEDX Group, Inc. | $5,250 | Consulting Fee | Cash or cash equivalent | BOVINE COLLAGEN Device, WOUND CARE | 2025 | |
| 2025-03-03 | MIMEDX Group, Inc. | $1,125 | Consulting Fee | Cash or cash equivalent | BOVINE COLLAGEN Device, WOUND CARE | 2025 | |
| 2025-03-03 | MIMEDX Group, Inc. | $750 | Consulting Fee | Cash or cash equivalent | BOVINE COLLAGEN Device, WOUND CARE | 2025 | |
| 2025-03-03 | MIMEDX Group, Inc. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,000 | Consulting Fee | Cash or cash equivalent | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $66 | Food and Beverage | In-kind items and services | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $44 | Food and Beverage | In-kind items and services | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $472 | Travel and Lodging | In-kind items and services | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $315 | Travel and Lodging | In-kind items and services | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $63 | Travel and Lodging | Cash or cash equivalent | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $46 | Travel and Lodging | In-kind items and services | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $32 | Food and Beverage | Cash or cash equivalent | LEVULAN KERASTICK Drug, Dermatology | 2025 | |
| 2025-02-27 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-02-26 | Biofrontera Inc. | $101 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-26 | MIMEDX Group, Inc. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-25 | Regeneron Pharmaceuticals, Inc. | $64 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-25 | Regeneron Pharmaceuticals, Inc. | $59 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-18 | Arcutis Biotherapeutics, Inc. | $5 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-02-17 | Lilly USA, LLC | $24 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-02-10 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $446 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $162 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $96 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $68 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $62 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-07 | Regeneron Pharmaceuticals, Inc. | $30 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-06 | MERZ NORTH AMERICA, INC. | $2,610 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-06 | Regeneron Pharmaceuticals, Inc. | $178 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-04 | UCB, Inc. | $32 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-01-22 | Solta Medical, a division of Bausch Health US, LLC | $2,175 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-01-19 | Arcutis Biotherapeutics, Inc. | $3,000 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-01-18 | PFIZER INC. | $105 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-01-15 | Regeneron Pharmaceuticals, Inc. | $396 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-01-10 | Regeneron Pharmaceuticals, Inc. | $84 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-10 | Regeneron Pharmaceuticals, Inc. | $28 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-10 | Regeneron Pharmaceuticals, Inc. | $28 | Travel and Lodging | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-10 | Regeneron Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-10 | Regeneron Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 |
The latest 200 records of 759.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-14 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $1,447 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-10-03 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $807 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $1,734 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-09-11 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $1,402 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-09-04 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $2,880 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-08-26 | Eli Lilly and Company | OAK DERMATOLOGY | $1,478 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $1,402 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | OAK DERMATOLOGY LLC | $4,729 | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-02-18 | Eli Lilly and Company | OAK DERMATOLOGY | $56,332 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH M | 2025 |
| 2021-04-13 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY | $2,200 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2021 |
| 2021-04-13 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY | $135 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2021 |
| 2021-01-19 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY | $2,243 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2021 |
| 2020-10-13 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $6,529 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-09-15 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $10,165 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-08-18 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $7,429 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-08-18 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $11,532 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-07-14 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $14,704 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-06-16 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $7,503 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-04-14 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $19,558 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-03-17 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $24,353 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-03-17 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $1,542 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-02-18 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $8,640 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2020-01-07 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $12,125 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2020 |
| 2019-05-21 | Endo Pharmaceuticals Inc. | OAK DERMATOLOGY LLC | $5,000 | A REAL WORLD, MULTICENTER, OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE EFFECTIVENESS OF, AND SATISFACTION WITH, CCH TR | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Itasca, IL, county DuPage County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Itasca, IL | County DuPage County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 9,355 | 930,024 | 12,694,798 |
| Population, 2020 census P1 | 9,543 | 932,877 | 12,812,508 |
| Median age B01002 | 43.1 | 40.2 | 39.0 |
| Under 18 B01001 | 21.0% | 22.2% | 21.8% |
| 65 and over B01001 | 14.6% | 17.3% | 17.0% |
| Households B11001 | 3,754 | 350,758 | 5,036,449 |
| Foreign born B05002 | 23.9% | 20.5% | 14.7% |
| Median household income B19013 | $114,294 | $112,096 | $83,390 |
| Median family income B19113 | $115,859 | $138,559 | $106,018 |
| Per capita income B19301 | $62,712 | $58,189 | $46,406 |
| Poverty rate B17001 | 2.0% | 6.6% | 11.8% |
| Unemployment rate B23025 | 2.6% | 4.9% | 5.8% |
| Civilian labor force B23025 | 5,463 | 509,668 | 6,652,134 |
| Mean commute (minutes) B08013 | 25.9 | 27.7 | 27.8 |
| Bachelor's degree or higher B15003 | 52.9% | 51.8% | 37.8% |
| Housing units B25001 | 4,087 | 367,152 | 5,457,452 |
| Owner-occupied B25003 | 69.3% | 73.1% | 67.1% |
| Renters B25003 | 30.7% | 26.9% | 32.9% |
| Median home value B25077 | $390,800 | $391,400 | $263,300 |
| Median gross rent B25064 | $1,892 | $1,688 | $1,274 |
| White, not Hispanic B03002 | 67.1% | 62.2% | 58.1% |
| Black B03002 | 0.4% | 4.8% | 13.3% |
| Hispanic or Latino B03002 | 13.7% | 16.1% | 18.8% |
| Asian B03002 | 13.3% | 13.0% | 5.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Itasca, IL.
Comments